

Medical Decision Making

<http://mdm.sagepub.com/>

Note from the Editors

Michael Drummond, Mark Helfand and C. Daniel Mullins
Med Decis Making 2012 32: 653
DOI: 10.1177/0272989X12458665

The online version of this article can be found at:
<http://mdm.sagepub.com/content/32/5/653>

Published by:



<http://www.sagepublications.com>

On behalf of:



<http://www.smdm.org>

Additional services and information for *Medical Decision Making* can be found at:

Open Access: Immediate free access via SAGE Choice

Email Alerts: <http://mdm.sagepub.com/cgi/alerts>

Subscriptions: <http://mdm.sagepub.com/subscriptions>

Reprints: <http://www.sagepub.com/journalsReprints.nav>

Permissions: <http://www.sagepub.com/journalsPermissions.nav>

>> [Version of Record](#) - Sep 18, 2012

[What is This?](#)

Note from the Editors

Michael Drummond, PhD, Mark Helfand, MD, MPH, C. Daniel Mullins, PhD

This issue contains seven articles that offer guidance for modeling studies for health outcomes research. To ensure that good research practices on modeling techniques remain useful for all current modeling techniques as well as to foster the use of model-based results to inform health care decisions, a Modeling Good Research Practices Task Force was created. The task force members consist of individuals from the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the Society for Medical Decision Making (SMDM), and the journals of both societies, *Value in Health* and *Medical Decision Making*, agreed to publish the task force reports on the same date in both journals after a period of peer review.

Thus, the seven articles from the ISPOR-SMDM Task Force are being published simultaneously in *Value in Health* and *Medical Decision Making*. Each manuscript was submitted to both journals simultaneously. Before submission, as part of the guidance development process, the manuscripts underwent review by a panel of reviewers. In addition, the membership of each society was invited to comment on them. The original journal submissions included the comments of the reviewers as well as the authors' responses to those comments.

Prior to submission, the wording of the task force's recommendations was approved by the leadership of ISPOR and SMDM. For this reason, the journals agreed, prior to submission, that we would not change or suggest changes to the wording of the

recommendations. However, we did provide opportunity for peer review of the write-up associated with the recommendations, since often the explanation and interpretation of recommendations are as important as the content of the recommendations themselves.

We assigned each manuscript to two editors, one from each journal. We alternated roles so that for some papers, the *Value in Health* editor had the first look, whereas for others, the *Medical Decision Making* editor did. In some cases, after review by an internal associate editor, the editors decided to send the manuscript to one of the panel reviewers, a new reviewer, or both. All manuscripts underwent one round of revision prior to final acceptance. Both editors signed each decision letter. Although *Value in Health* had a prior agreement with ISPOR to publish all papers submitted, and *Medical Decision Making* followed its usual editorial policy regarding invited material, the editors of the two journals collaborated at every step, and, as it happens, all decisions were mutual.

After acceptance of the papers, each journal followed its usual policies for journal style and copyediting, which may have resulted in differences in formatting. The editors did not review the proofs from the other journal, but J. Jaime Caro, the leader of the task force, approved the proofs for both journals. The two journals also used different procedures for disclosure of conflicts of interest.

CONFLICT OF INTEREST DISCLOSURE

Paper Title: Modeling Good Research Practices—Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force–1

Author: **J. Jaime Caro**—no conflict

Author: **Andrew H. Briggs**—no conflict

Author: **Karen M. Kuntz**—no conflict

Paper Title: Conceptualizing a Model: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force–2

Author: **Mark Roberts**

Model or Product Name: Braithwaite HIV Model

Role: Co-Investigator of one NIH K award and on NIH R award that funded the development of this model (K23 AA14483 and R01AA017385-01)

Author: **Louise B. Russell**—no conflict

Author: **A. David Palteil**

The report of Working Group 2 (Conceptual Modeling) refers to the report of Working Group 6 (Parameter Estimation and Uncertainty). David is an author on both reports.

Author: **Michael Chambers**

Model or Product Name: H1N1 Vaccination for epidemic influenza, subject of model based cost-effectiveness analysis (Sander et al Vaccine 2010;28:6210-20)

Role: Employee of GlaxoSmithKline, which is a manufacturer of H1N1 vaccine, referred to in Section 2. Conceptualization of the problem. *NB In the source study referenced (ref 10) the manufacturer of H1N1 vaccine is not named and GlaxoSmithKline had no involvement in this study*

Model or Product Name: Antiretroviral therapy for HIV disease, for which various modelled evaluations are referenced in the Appendix to the paper

Role: Employee of GlaxoSmithKline, which in a joint venture with Pfizer (ViiV) is a manufacturer of antiretroviral therapies, some of which are referred to by studies referenced in the Appendix. *NB To my knowledge GlaxoSmithKline had no involvement in any of the studies referenced.*

Author: **Murray Krahn**—no conflict

Paper Title: State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force–3

Author: **Oguzhan Alagoz**—no conflict

Author: **Ahmed M. Bayoumi**—no conflict

Author: **Beate Jahn**—no conflict

Author: **Douglas K. Owens**—no conflict

Author: **David J. Cohen**—no conflict

Author: **Karen M. Kuntz**—no conflict

Paper Title: Modeling Using Discrete Event Simulation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force–4

Author: **Jonathan Karnon**—no conflict

Author: **James Stahl**—no conflict

Author: **Alan Brennan**—no conflict

Author: **J. Jaime Caro**—no conflict

Author: **Javier Mar**—no conflict

Author: **Jörgen Möller**—no conflict

Paper Title: Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5

Author: **Richard Pitman**—no conflict
Author: **David Fisman**—no conflict
Author: **Gregory S. Zaric**—no conflict
Author: **Maarten Postma**—no conflict
Author: **Mirjam Kretzschmar**—no conflict
Author: **John Edmunds**—no conflict
Author: **Marc Brisson**—no conflict

Paper Title: Modeling Parameter Estimation and Uncertainty Analysis: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6

Author: **Andrew H. Briggs**—no conflict
Author: **Milton C. Weinstein**—no conflict
Author: **Elisabeth A. L. Fenwick**—no conflict
Author: **Jonathan Karnon**—no conflict
Author: **Mark J. Sculpher**—no conflict
Author: **A. David Paltiel**

The report of Working Group 2 (Conceptual Modeling) refers to the report of Working Group 6 (Parameter Estimation and Uncertainty). David is an author on both reports.

Paper Title: Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7

Author: **David M. Eddy**
Model or Product Name: Archimedes Model
Role: Founder and Chief Medical Officer Emeritus of Archimedes Inc, and co-builder of Archimedes
Author: **William Hollingworth**—no conflict
Author: **J. Jaime Caro**—no conflict
Author: **Joel Tsevat**—no conflict
Author: **Kathryn M. McDonald**—no conflict
Author: **John B. Wong**

Model or Product Name: Rheumatoid Arthritis Model

Role: Principal investigator and investigator of grants to develop a rheumatoid arthritis cost-effectiveness model and to compare published rheumatoid arthritis cost-effectiveness models